FibroGen (NASDAQ:FGEN) Posts Quarterly Earnings Results, Beats Expectations By $0.21 EPS

FibroGen (NASDAQ:FGEN) announced its earnings results on Tuesday. The biopharmaceutical company reported ($0.17) EPS for the quarter, beating the consensus estimate of ($0.38) by $0.21, Zacks reports. The business had revenue of $46.33 million for the quarter, compared to the consensus estimate of $34.00 million. During the same quarter in the previous year, the company earned ($0.52) EPS.

FibroGen Price Performance

Shares of FGEN stock traded down $0.03 during trading hours on Wednesday, reaching $0.36. The company had a trading volume of 2,529,472 shares, compared to its average volume of 2,225,580. FibroGen has a 12 month low of $0.29 and a 12 month high of $2.93. The business has a fifty day simple moving average of $0.37 and a 200-day simple moving average of $0.72. The company has a market cap of $36.15 million, a price-to-earnings ratio of -0.30 and a beta of 0.72.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the company. StockNews.com assumed coverage on FibroGen in a research report on Wednesday, November 6th. They set a “hold” rating on the stock. William Blair reiterated a “market perform” rating on shares of FibroGen in a report on Wednesday.

About FibroGen

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.